1. Home
  2. SCS vs AKBA Comparison

SCS vs AKBA Comparison

Compare SCS & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCS
  • AKBA
  • Stock Information
  • Founded
  • SCS 1912
  • AKBA 2007
  • Country
  • SCS United States
  • AKBA United States
  • Employees
  • SCS N/A
  • AKBA N/A
  • Industry
  • SCS Office Equipment/Supplies/Services
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SCS Consumer Discretionary
  • AKBA Health Care
  • Exchange
  • SCS Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • SCS 1.2B
  • AKBA 958.6M
  • IPO Year
  • SCS 1998
  • AKBA 2014
  • Fundamental
  • Price
  • SCS $10.22
  • AKBA $3.68
  • Analyst Decision
  • SCS Strong Buy
  • AKBA Strong Buy
  • Analyst Count
  • SCS 2
  • AKBA 5
  • Target Price
  • SCS $17.00
  • AKBA $6.90
  • AVG Volume (30 Days)
  • SCS 711.5K
  • AKBA 6.1M
  • Earning Date
  • SCS 06-25-2025
  • AKBA 08-07-2025
  • Dividend Yield
  • SCS 3.93%
  • AKBA N/A
  • EPS Growth
  • SCS 50.00
  • AKBA N/A
  • EPS
  • SCS 1.02
  • AKBA N/A
  • Revenue
  • SCS $3,166,000,000.00
  • AKBA $184,909,000.00
  • Revenue This Year
  • SCS $4.20
  • AKBA $26.88
  • Revenue Next Year
  • SCS $4.09
  • AKBA $44.34
  • P/E Ratio
  • SCS $9.97
  • AKBA N/A
  • Revenue Growth
  • SCS 0.20
  • AKBA N/A
  • 52 Week Low
  • SCS $9.32
  • AKBA $0.80
  • 52 Week High
  • SCS $14.74
  • AKBA $4.08
  • Technical
  • Relative Strength Index (RSI)
  • SCS 46.85
  • AKBA 64.49
  • Support Level
  • SCS $10.12
  • AKBA $3.46
  • Resistance Level
  • SCS $10.89
  • AKBA $3.98
  • Average True Range (ATR)
  • SCS 0.26
  • AKBA 0.25
  • MACD
  • SCS -0.03
  • AKBA -0.04
  • Stochastic Oscillator
  • SCS 13.46
  • AKBA 64.20

About SCS Steelcase Inc.

Steelcase Inc is a furniture company based in the United States. Its brands, such as Steelcase, AMQ, Coalesse, Designtex, and others, offer a portfolio of furniture and architectural products and services designed to help customers create workplaces. It markets its products and services to businesses and organizations predominantly through a network of dealers and also sells to consumers in markets around the world through web-based and retail distribution channels. The company's reportable segments include the Americas, which generates key revenue, and the International segment.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: